1. Beveridge WIB. Influenza: The Last Great Plague. An unfinished story of discovery. London: Heineman, 1977.

2. Rodnguez Torres A. Epidemiología y ecología de la gnpe A. Valladolid: Sever-Cuesta, 1982.

3. Kaplan MW, Webster RG. La epidemiología de la gnpe. Invest Ciencia 1978;17: 52-63.

4 Hinshaw VS, Bean WJ, Webster RG, Easterday BC. The prevalence of influenza viruses in swine and the antigenic and genetic relatedness of influenza viruses from man and swine. Virology 1978; 84: 51-59.

5 Tautenberger JK, Reid AH, Krafft AE, Buwaard KE, Fanning TG. Initial genetic characterization of the 1918 «spanish» influenza virus. Science 1997; 275: 1793-1796.

6. Dowdle WR, Coleman MT. Properties of the Hong Kong influenza virus. 2. Antigenic relationship of the Hong Kong virus hemagglutinin to that other human influenza A viruses. Bull WHO 1969; 41:419424.

7. Pumarola A, Rodriguez Torres A, Beltrán M. La gnpe Hong Kong en Barcelona. Med Trop 1970; 14: 221-250.

8. Pumarola A, Rodríguez Torres A. Anticuerpos inhibidores de la hemaglutinación del virus gnpal A2 en la población de Barcelona Med Clin (Barc) 1969; 52:489-494.

9. Kendal AP, Goldfield M, Noble GR, Dowdle WR. Identification and preliminary analisis of swine influenza-like virus isolated during an influenza outbreak at Fort Dix, New Jersey.34. J Infect Dis 197 z (suppl): 381-394.

10. Rodriguez Torres A, Ortíz de Lejarazu R. Anticuerpos frente a la gripe porcina y humana en la población de Valladolid. Med 35. Clin (Bare)1977; 68: 16-18.

11. Kung HC, Jen KF, Yuan WC, Tien SF, Chu CM. Influenza in China in 1977: Recurrence of influenza virus A subtipe HlN1. Bull WHO 1978; 56: 913-918.

12. Zakstelskaja LJA, Yakno MA, Isacenko V et al. Influenza in the USSR in 1977: Recurrence of influenza virus A subtype HlN1. Bull WHO 1978; 56: 918-922.

13. Zhadanov VM. Live influenza vaccines in USSR. Development of studies and practical application. En: Kendal AP, Patriarca AP, eds. Options for the control of influenza New York: Alan R. Liss, 1986; 193-206. 38.

14. Maassab HF, La Montagne JR, DeBorde DC. Live influenza virus vaccines. En: Plotkin SA, Mortimer EA, eds. Vaccines, Philadelphia WB Saunders, 1988; 435-457.

15. Murphy FA, Fauquet CM, Bishop DHL et al, eds. Virus taxonomy. Sixth Report of the International Committee on Taxonomy of Viruses. Family Orthomyxoviridal. Arch Virol 1995 40.(suppl 10): 293-299.

16. Larnb RA, Krug RM. Orthomyxoviridae. The viruses and their replication. En: Fields BN, Knipe DM, Howley PM, eds. Virology, 3 a ed. New York: Lippincot-Raven, 1996; vol 1, 1353-1395.

17. Murphy BR, Webster RG. Orthomyxoviruses En: Fields BN, Knipe DM, Howley PM, eds. Virologs; 3 a ed. New York: Lippincot-Raven, 1996; vol 1, 1397-1445.

18. Shaw MW, Arden NH, Maassab HF New aspects of influenza viruses. Clin Microbiol Rev 1992; 5: 74-92.

l9. Laver WG. The hemagglutinin of influenza viruses: Structure, immunology and biological function. J Infect Dis 1978; 138: 105-109.

20. Air GM, Laver WG. The neuraminidase of influenza virus. Proteins Struct Funct Genet 1989; 6: 341-356.

21. Palese P. The genes of influenza virus. Cell 1977; 10: 1-10.

22. Scholtissek C. Influenza virus genetics. Adv Genet 1979; 20: 149.

23. WHO memorandum. A revision of the system of nomenclature for influenza virus. Bull WHO 1980; 58: 585-591.

24. Rohm C, Zhou N, Suss J, Mackenzie J, Webster RG. Characterization of a novel influenza hemagglutinin, H15: Critena for detennination of influenza subtypes. Virology 1996; 217: 508 51G.

25. Wiley DC, Wilson IA, Skehel JJ. Structural identification of the antibodies binding sites of the Hong Kong influenza hemagglutinin and their involvement in antigenic variation. Nature 1981; 289: 373-377.

26. Aymard M, Coleman MT, Dowdle WR, Laver WG, Schild GC,Webster RG. Influenza virus neuraminidase inhibition test procedures. Bull WHO 1973; 48: 199-202.

27. Palese P, Young JF. Variation of influenza A, B and C viruses. Science 1982; 92: 1468-1474.

28. Laver WG, Air GM, eds. Structure and variation in influenza virus. New York: Elsevier North Holland, 1980.

29. Webster RG, Laver WG, Air GM, Schild GC. Molecular mechanisms of variation in influenza viruses. Nature 1982; 296: 115-121.

30. Young JF, Palese P. Evolution of human influenza A viruses innature. Recombination contnbutes to genetic variation of HlN1 strains. Proc Natl Acad Sci USA 1979; 76: 6547-6551.

31. Bean WJ Jr, Cox NJ, Kendal AP. Recombination of human influenza A viruses in nature. Nature 1980; 284: 638-640.

32. Scholtissek C. Evolution of pandemic influenza virus strains.:Philos Trans R Soc Lond Biol 1980; B288: 307-312.

33. Rott R, Klenk HD, Scholtissek C. Activation of influeriza infectivity by proteolitic cleavage of the hemagglutinin. Top Infect Dis 1978; 3: 69-81.

34. Rott R. Genetic determinants for infectivity and pathogenicity of influenza viruses. Philos Trans R Soc Lond Biol 1980; B288: 393-399.

35. Newman RW, Jennings R, Major DL et al. Immune responseof human volunteers and animals to vaccination with egg grown influenza A (HlN1) virus is influenced by three aminoacid substitutions in the hemagglutinin molecule. Vaccine 1993; 11: 400-406.

36. Betts RF. Influenza virus. En: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 4 a ed. New York: Churchill Livingstone, 1995; vol 2, 1546-1563.

37. Kerr A, Downham MAPS, McQuillin J, Gardner PS. Gastncflu: Influenza B causing abdominal symptoms in children. Lancet 1975; i: 291-295.

38. Kim HW, Brandt CD, Arrobio JO, Murphy B, Chanock RM, Parrott RH. Influenza A and B virus infection in infants and young children during the years 1957-1976. Am J Epidemiol 1979; 109: 464-479.

39. Centers for Disease Control and Prevention. Reye Syndrome United States. MMWR 1979; 28: 97-105.

40. Hurwitz ES, Nelson DB, Davis C, Morens D, Schonberger LB.National surveillance for Reye's syndrome: A five-year review Pediatrics 1982; 70: 895-900.

41. Lichstenstein PK, Henbi JE, Daugherty CC et al. Grade 1 Reye's syndrome. A frequent cause of vomiting and liver dysfunction after varicella and upper-respiratory-tract infection.N Engl J Med 1983; 309: 133-139. . L

42. Waldman RJ, Hall WN, McGee H et al. Aspirin as a risk factor in Reye's syndrome. JAMA 1982; 247: 3089-3096: 111

43. Frank AL, Taber LH, Porter CM. Influenza B virus reinfection. Am J Epidemiol 1987; 125: 576-586

44. Davies JR, Grilli EA, Smith AJ. 1. Infection with influenza A HlN1. 2. The effect of past experience on natural challenge. J71 Hyg (Camb) 1986; 96: 345-352. 0~ L

45. Skoner DP, Whiteside TL, Wilson JW, Doyle WJ, Herberman RB, Fireman P Effect of influenza A virus infection on natural and adaptative cellular immunity. Clin Immunol Immunopathol 1996; 79: 294-302.

46. McElhaney JE, Meneilly GS, Lechelt KE, Bleackley C. Split-virus influenza vaccines: Do they provide adequate immunity in the elderly? J Gerontol Med Sci 1994; 49: M37-M43.

47. Greenberg SB, Krilov LR. Laboratory diagnosis of viral respiratory diseases. Cumulative techniques and procedures in clinical microbiology. Washington: ASM Press, 1986.

48. Harmon MW Influenza viruses. En: Lennette EH ed. Laboratory diagnosis of viral infections, 2 a ed. New York: Marcel Dekker, 1992; 515-534.

49. Ziegler T, Cox NJ. Influenza viruses. En: Murray PR Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology, 6.8 ed. Washington: ASM Press 1995; 918-925.

50. Webster RG, Bean WJ Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecoiogy of influenza A viruses. Microbiol Rev 1992; 56: 152-179.

51. Ghendon Y: Influenza. Its impact and control. World Health Stat Q 1992, 45: 306

52. Ghendon Y. Influenza surveillance. Bull WHO 1991, 69: 509-515.

53. La Force MF, Nichol KL, Cox NJ. Influenza: Virology, epidemiology disease and prevention. Am J Prev Med 1994; 10(suppl): 31-44.

54. USA Institute of Medicine. Committe on Issue and Priorities for New Vaccine Developement. New vaccine development stablishing prionties 1985-87. 1. Diseases of importance in the United States. Washington: National Academy of Sciences, 1985.

55. Collins SD. Excess mortality from causes other than influenza and pneumonia during influenza epidemics. Public Health Rep 1932; 46: 2159-2180.

56. Housworth J Langmuir AD. Excess mortality from epidemic inlluenlz.l L9.~l-1966. AmJ Epidemiol 1974; 100: 4048.

57. Choi K. Thacker SB. Mortality dunng influenza epidemies in the United States, 1967-1978. Am J Public Health 1982; 72: 1780.

58. Center for Disease Control and Prevention. Annual Summary. MMWR 1982; 30: 117.

59. Alling DW, Blackwelder WG, Stuart-Harris CH. A study of execes mortality during influenza epidemics in the United States, 1968- 1976. Am J Epidemiol 1981; 113: 3043.

60. Center for Disease Control and Prevention. Prevention and Control of influenza. Part I, vaccines. Recomendations of the Advisory Commitee on Immunization Practices (ACIP). MMWR 1996; 45: 1-23.

61. Sprenger MJW, Mulder PGH, Beyer WEP, Van Strik R, Masurel N. Impact of influenza on mortality in relation to age and underlying disease 1967-1989. Int J Epidemiol 1993; 2: 334-339.

62. Carrat F, Valleron AJ. Influenza mortality among the elderly in France, 1980-1990: How many deaths may have been avoided through -~accination? J Epidemiol Community Health 1995; 49:419425.

63. Langmuir AD. William Farr: Founder of modern concepts of surveillance. Int J Epidemiol 1976; 5: 13-18.

64. Clifford RE, Smith JWG, Tillet HE. Excess mortality associated with influenza in England and Wales. Int J Epidemiol 1977; 6: 115-128.

65. Tillet HE, Smith JWG, Clifford RE. Excess morbidity and mortality associated with influenza in England and Wales. Lancet 1980; 1: 793-795.

66. Lui KJ, Kendal AP. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public Health 1987; 77: 712-716.

67. Choi K, Thacker SB. An evaluation of influenza mortality surveillance 1962-1979. I. Time series forecasts of expected pneumonia and influenza deaths. Am J Epidemiol 1981; 113: 215-226.

68. Choi K, Thacker SB. An evaluation of influenza on mortality surveillance 1962-1979. II Percentage of pneumonia and influenza deaths as an indicator of influenza activity. Am J Epidemiol 1981; 113: 227-235.

69. Box GEP, Jenkins GM. Time series analysis forecasting and control. San Francisco: Holden Day, 1976.

70. Vidal Tort J. La gripe, un problema pendiente. Med Clin (Barc) 1991; 96: 60-62.

71. Lennox JM, Macphee GJA, McAlpine CH, Cameron SO, Leask BGS, Sommerville RG. Use of influenza vaccine in long stay genatncs units. Age Ageing 1990; 19: 169-172.

72. Nicholson KG, Wiselka MJ, May A. Influenza vaccination of the elderly persons: Perceptions and policies of general practitioners and outcome of the 1985-86 immunization programme in Trent U K. Vaccine 1985; 5: 302-306.

73. Schoenbaum SC. Economic impact of influenza. The individual perspective. Am J Med 1987; 82 (suppl 6A): 26 30.

74. Valleron AJ, Garnerin P. Computer networking as a tool for public health surveillance: The French experiment. MMWR 1992, 41 (suppl): 101-110.

75. Glezen WP, Decker M, Joseph SW, Mercready RG. Acute respiratory disease associated with influenza epidemics in Houston 1981-1983. J Infect Dis 1987, 155: 1119-1126.

76. Glezen WP, Paredes A, Taber LH. Influenza in children: Relationship to other respiratory agents. JAMA 1980; 243: 1345-1349.

77. Barker WH. Excess pneumonia and influenza associated hospitalization during influenza A epidemics in the US, 1970-1978. En: Kendal AP, Patriarca PA, eds. Options for the control of influenza New York: Alan R Liss, 1986; 75-88.

78. Williams WW, Hickson MA, Kane MA, Kendal AP, Spika JS,Hinman AR. Immunization policies and vaccine coverage among adults: The risk for missed opportunities. Ann Intern Med 1988; 108: 616-625.

79. Organización Panamencana de la Salud. Sistemas de vigilancia epidemiológica de las enfermedades transmisibles y zoonosis. Publicación Científica 288. Washington: Organización Panamericana de la Salud, 1974.

80. Serfling RE. Methods for current statistical analysis of excess pneumonia influenza deaths. Public Health Rep 1963; 78: 494-506.

81. World Health Organization. Surveillance of influenza in the European region. Wkly Epidemiol Rec 1992; 67: 49-50.

82. Hannoun C, Dad W, Cohen JM. A new influenza surveillance system in France: The Ile-de-France «Grog» I. Principles and methodology. Eur J Epidemiol 1989; 5: 285-293.

83. Barker WH, Menegus MA, Hall CB et al. Communitywide laboratory-based influenza surveillance focused on older persons, 1989-1992. Am J Prev Med 1995; 11: 149-155.

84. Chakraverty P. Surveillance of influenza in the United Kingdom. Eur J Epidemiol i994; 10: 493-495.

85. Chauvin P. Constitution and monitoring of an epidemiologica surveillance network with sentinel general practitioners. Eur J Epidemiol 1994; 10: 477479.

86. Szecsenyi J, Uphoff S, Ley S, Brede HD. Influenza surveillance: Experiences from establishing a sentnel surveillance system in Germany. J Epidemiol Community Health 1995; 49 (suppl 1): 9-13.

87. Valeron AJ, Bouvet E, Garnerin P et al . A computer network for the surveillance of communicable diseases: The French experiment. Am J Publlic Health 1986; 76: 1289-1292.

88. Friede A, Reid JA, Ory HW. CDC Wonder A comprehensive on-line public health information system of the Center for Disease Control and Prevention. Am J Public Health 1993; 83: 1289-1294.

89. Ortíz de Lejarazu R, Rodríguez Torres A, Beltrán M. Resultados de la vigilancia de la gripe en Valladolid desde 1972 a 1984. Aspectos actuales en biología y medicina. Libro homenaje al profesor A. Pumarola. Valladolid: Sever Cuesta, 1984; 453458.

90. Snacken R, Capet F, Stroobant A. Usage du vidéotex en santé publique. Techn Sante 1993; 14: 47-50.

91. Sprenger MJW, Kempen BM, Hannoun C, Masurel N. Electronic influenza surveillance. Lancet 1992; 339: 874.

92. Snacken R, Bensandon M, Strauss A. The CARE telematics network for the surveillance of influenza in Europe. Methods Inf Med 1995; 34: 518-522.

93. Pumarola A, Rodriguez Torres A, Vidal J, Orta J. Estudio etiológico del brote epidemiológico gripal ocurrido en Barcelona en Febrero de 1968. Microbiol Esp 1969; 22: 233249.

94. Rodríguez Torres A. Estudio biológico de un brote epidémico de gripe asiática An Med Cirug (Barcelona), 1967; 47: 227-257.

95. Departament de Sanitat i Seguretat Social. Activitat gripal a l'Area de Barcelona Temporada 1995-1996. Butlleh Epidemiologic de Catalunya 1996; XVI: 85-90.

96. Consejeria de Cultura y Bienestar Social. Subprograma de control de la gripe. Boletin Epidemiológico de Castilla y León, 1987; 3: 163-170.

97. Ordobás MA, Zorrilla B, Arias P. Influenza in Madrid, Spain, 1991-92: Validity of the sentinel network. J Epidemiol Community Health 1995; 49 (suppl 1): 1s16.

98. Kaplan MM. The role of World Heath Organization in the study of influenzaPhilos Trans R Soc Lond Biol 1980; 288: 417421.

99. Snacken R, Lion J, Van Casteren V et al. Five years of sentinel surveillance of acute respiratory infections (1985-1990): The benefits of an early warning system. Eur J Epidemiol 1992; 8:485490.

100. Katz JM, Webster RG. Efficacy of inactvated influenza virus (H3 N2) vaccines grown in mammalian cells or embryonated eggs. J Infect Dis 1989; 160: 191-198.

101. Robertson JS, Bootman JS, Newman RW et al. Structural changes in the haemagglutinin of influenza A (HlN1) virus which accompany egg-adaptation. Virology 1987; 160: 31-37.

102. World Health Organization. Recommended composition of influenza virus vaccines for use in the 1997-1998 season. Wkly Epidemiol Rec 1997; 9: 57-61.

103. Kilbourne ED. Future influenza vaccines and use of genetic recombinants. Bull WHO 1969; 41: 643-645.

104. Reimer CB, Baker RS, Newlin TE, Havens ML. Influenza virus purification with the zonal ultra-centrifuge. Science 1966; 152: 1379-1381.

105. Wood JM, Schild GC, Newman RW, Seagroatt V. An improved single radial immunodiffusion technique for the assay of influenza haemagglutinin antigen: Application for potency determinations of inactivated whole and subunit vaccines. J Biol Stand 1977; 5: 237-247.

106. Nicholson KG, Snacken R, Palache AM. lnfluenza immunization policies in Europe and the United States. Vaccine 1995; 13: 365-369.

107. Freeman DW, Barno A. Deaths from Asian influenza associated with pregnancy. Am J Obstet Gynecol 1959; 78: 1172-1175.

108. Ashley J, Smith T, Dunell K. Deaths in Great Britain associated with the influenza epidemic of 1989/90. Popul Trends 1991; 65: 16-20.

109. Deinhard AS, Ogburn P Jr. A/NJ/8/76 influenza vaccination program: Effects on maternal health and pregnancy outcome. Am J Obstet Gynecol 1981; 140: 240-245.

110. Safrin S, Rush J, Mills J. Influenza in patients with human immunodeficiency virus infection. Chest 1990; 90: 33-37.

111. Yerly S, Wunderli W. Wyler CA et al. Influenza immunization of HIV-1 infected individuals does not increase HIV 1 viral load. AIDS 1994; 8: 1503-1504.

112. Staprans SI, Hamilton BL, Follansbee SE et al. Activation of virus replication after vaccination of HIV-1 infected individuals. J Exp Med 1995; 182: 1727-1737.

113. O' Bnen WA, Grovit-Ferbas K, Namazi A et al. Human immunodeficiency virus-type replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995; 86: 1082-1089.

114. Huang K, Ruben FL, Rinaldo CR, Kingsley L, Lyter DW, Ho M. Antibody responses after influenza and pneumococcal immunization in HIV infected homosexual men. JAMA 1987; 257: 2047-2050.

115. Nelson KE, Clements M, Miotti P, Chon S. Influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines. Ann Intern Med 1988; 109: 383-388.

116. Miotti PG, Nelson KE, Dallabeta GA, Farzadegan H, Margolick J, Clements M. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA 1989; 262: 779-783.

117. Barry DW, Mayner RE, Hockstein HD et al: .Comparative trial of influenza vaccines. 11 Adverse reactions in children and adults. Am J Epidemiol 1976; 104: 47-59.

118. Gross PA. Reactogenicity and immunogenicity of bivalent influenza vaccine in one and two dose trials in children. A summary. J Infect Dis 1977; 136 (suppl): S616-625.

119. Wright FW, Thompson J, Vaughn WK. Folland DS, Sell SHW, Karzon DT. Trials of influenza A/Nev.~ Jersey/76 virus vaccine in normal children: An over-view of age related antigenicity and reactogenicity. J Infect Dis 1977; 136: 731-741.

120. Groothuis JR, Levin MJ, Rabalais GP, Meiklejohn G, Lauer BA. Immunization of high-nsk infants younger than 18 months with split-product influenza vaccine. Pediatrics l991; 87: 823-828.

121. Rentero DB, Tenias JM, Sabater A, Pérez B, Zanón V. Comparación de las reacciones adversas a las vacunas antigripales de virus fraccionados y de antígenos de superficie. Rev Esp Salud Publica 1995; 69: 463-468.

122. Bernard M, Nuñez JC, Castillo O, González MC, García B. Reacciones adversas con diferentes tipos de vacuna antigripal. Med Clin (Barc) 1996; 106: 11-14.

123. Murphy KR, Strunt RC. Safe administration of influenza vaccine in asthmatic children hypersensitive to eggs proteins. J Pediatr 1985; 106: 931-933.

124. Center for Disease Control and Prevention. Follow-up on Guillain-Barré syndrome. United States. MMWR 1977; 26: 52.

125. Safranek TJ, Lawrence DN, Kurland LT et al. Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccine in 1976-1977: Results of a two-state study. Am J Epidemiol 1991; 133: 940-951.

126. Jani FM, Gray JP, Lanham J. Influenza vaccine and dermatomyositis. Vaccine 1994; 12: 1484.

127. MacKenzie WB, Davis JP, Peterson DE, Hibbard AJ, Becker G, Zarvan BS. Multiple false-positive serologic tests for HIV, HTLV-I and hepatitis C following influenza vaccination 1991. JAMA 1992; 268: 1015-1017.

128. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination inhibition antibody in protection against challenge infection with A2 and B viruses. J Hyg (Camb) 1972; 70: 767-777.

129. Govaert ME, Sprenger MJW, Dinant GJ, Aretz K, Masurel N, Knottnerus JA. Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial. Vaccine 1994; 12: 1185-1189.

130. Potter CW, Jennings R, Mclaren C, Edey D, Stuart-Harris CH. A new surface antigen adsorbed influenza virus vaccine: II studies in a volunteer group. J Hyg (Camb) 197a; 75: 353-362.

131. Dowdle WR. Influenza immunoprophylaxis after 30 years expenence. En: Nayak DP, ed. Genetic variation among influenza viruses. New York: Academic Press. 1981; 525-534.

132. Strassburg MA, Greenland S, Sorvillo FJ, Lieb LE. Habel 1,A.Influenza in the elderly: Report of an outbreak and a review of vaccine effectiveness reports. Vaccine 1986; 4: 38-44. 5

133. Keren G, Segev S, Morag A, Zakay-Rones Z. Barzilai A. Rubinstein A: Failure of influenza vaccination in the aged. J Med Virol 1988; 25: 85-89.

134. Mostow SR, Schoenbaum SC, Dowdle WR, Coleman MT, Kaye HS Studies with inactivated influenza vaccines purified by zonal centnfugation. 1. Adverse reactions and serological responses. Bull WHO 1969; 41:525.

135. Gross PA, Quinnan GV, Weksler ME, Gaerlan PF, Denning CR. Immunization of elderly people with high doses of influenza vaccine. J Am Genatr Soc 1988; 36: 209-212.

136. Gross PA, Weksler ME, Quinan GUJr, Doublas RGJr, Gaerlan PF, Denning CR. Immunization of elderly people with two doses of influenza vaccine. J Clin Microbiol 1987; 25: 17631769.

137. Beyer WEP, Palache AM, Baljet M, Masurel N. Antibody induction by influenza vaccines in the elderly: A review of the literature. Vaccine 1989; 7: 385-394.

138. Palache AM, Beyer WEP, Sprenger MJW et al. Antibody response after influenza immunization with various vaccine doses: A double-blind, placebo-controlled, multi-center, doseresponse study in elderly nursing-home residents and young volunteers. Vaccine 1993; 11: 3-9.

139. Gross PA, Lee H, Wolff HA, Hall CB, Minnefore AB, Lazicki ME. Influenza immunization in immunosupressed children. J Pediatr 1978; 92: 30-35.

140. Ortbals DW, Liebhaber H, Presant CA, Van Amburg AL. Influenza immunization of adult patients with malignant diseases. Ann lntern Med 1977; 87: 522-557.

141. Blumberg EA, Albano C, Pruett T et al. The immunogenicitY of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis 1996; 22: 295-302.

142. Feery BJ, Hartman LJ, Hampson AW, Proietto J. Influenza immunization in adults with diabetes mellitus. Diabetes Care 1983; 6: 475-478.

143. Bayer WEP, Versluis DJ, Kramer P, Diderich Ph PMN, Weimar W, Masurel N. Trivalent vaccine in patients on haemodialysis: Impaired seroresponse with differenees for A/H3N2 and A/HlNl vaccine component. Vaccine 1987; a: 4348.1-14.

144. Palache AM, Beyer WEP, Luchters G, Volker R, Sprenger MJW, Masurel N. Influenza vaccines: The effect of vaccine dose on antibody response in primed populations dunng the ongoing interpandemic penod. A review of the literature. Vaccine 1993; 11: 892-908.

145. Oxford JS, Haaheim LR, Slepushkin A, Werner J, Kuwert E, Schild GC. Strain specificity of serum antibody to the haemagglutinin of influenza A (H3N2) viruses in children following immunization or natural infection. J Hyg (Camb) 1981;86: 17-26.

146. Webster RG, Kasel JA, Couch RB, Laver WG. Influenza virus subunit vaccines: II. Immunogenicity and original antigenics in in humans. J Infect Dis 1976; 134: 48-58.

147. Hoskins TW, Davies JR, Smith AJ, Miller CL, Allchin A. Assessment of inactivated influenza A vaccine after three outbreaks of influenza A at Christ's Hospital. Lancet 1979; 1: 33-35.

148. Feery BJ, Evered MG, Morrison E. Different protection rates in vanous groups of volunteers given subunit influenza virus vaccine in 1976. J Infect Dis 1979; 139: 237-241.

149. Keitel W, Cate TR, Couch RB. Efficacy of sequential annual vaccination with inactivated influenza virus vaccine. Am J Epidemiol 1988; 127: 353-364.

150. Potter CW, Jennings R, Nickolson K, Tyrrel DAS, Dickinson KG. Immunity to attenuated inlluenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines. J Hyg (Camb) 1977; 79: 321-332.

151. Goodeve A, Potter CW, Clark A, Jennings R, Schild GC, Yetts R. A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: Reactogenicity, antibody response and protection to challenge virus infection. J Hyg (Camb) 1983; 90: 107-115.

152. Govaert ME, Thus CTMCN, Masurel N, Sprenger MJW, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled tnal. JAMA 1994; 272: 1661-1665.

153. Foster DA, Talsma A, Furumoto-Dawson A et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1992; 136: 296-307.

154. Fedson DS, Wajda A, Nicol P, Hammond GW, Kaiser DL, Ross LL. Clinical effectiveness of influenza vaccination in Manitoba JAMA 1993; 270: 1956-1961.

155. Nichol KL, Margolis MD, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331: 778-784.

156. Mullooly JP, Bennett MD, Hornbrook MC et al. Influenza vaccination programs for elderly persons: Cost-effectiveness in a health maintenance organization. Ann Intern Med 1994; 121: 947-952.

157. Ohmit SE, Monto AS. Influenza vaccine effectiveness in preventing hospitalization among the elderly dunng innuenza type A and type B seasons. Int J Epidemiol 1995; 24: 1240-1248.

158. Ahmed AEH, Nicholson KG, Nguyen-Van-Tam JS. Reduction in mortality associated with influenza vaccine durulg 1989 90 epidemic. Lancet 1995; 346: 591-595.

159. Gross PA, Hermogenes AW, Sacks HS, Lau J, Lewandowski RA. The efficacy of inlluenza vaccine in elderly persons. A meta-analysis and review of the literature. An Int Med 1995;123: 518-527.

160. Nichol KL, Lind A, Margolis KL et al. The effectiveness of vaccination against influenza in healthy working adults. N Engl J Med. 1995: 333: 889-893.

161. Of fice of Technology Assessment, US Congress. Cost effectiveness of influenza vaccination. Washington: USA Govemment Printing Office, 1982.

162. Koplan JP, Axnick NW. Benefits, nsks and costs of viral vaccines. Progr Med Virol 1982; 28: 180-191.

163. Barber WH, Mullooly JP. Pneumonia and influenza deaths during epidemies: Implications for prevention. Arch Intem Med 1982; 142: 85-89.

164. Helliwell BE, Drummond MF. The cost and benefits of preventing influenza in Ontario's elderly. Can J Public Health 1988; 79: 75-79

165. Kunnczuk JJ, Nicholson KG. Uptake of influenza vaccination by patients with serious cardiac disease. Br Med J 1989; 299:367.

166. Russell LB. Oportunity costs in modem medicine. Health Aff (Millwood) 1992; 11: 162-169.

167. Center for Disease Control and Prevention. Final results: Medicare influenza vaccine demonstration-selected states. 1988-1992. MMWR 1993; 42: 601-604.

168. Nguyen-Van-Tam JS, Nicholson KG. Influenza inlmunizahons: Vaccine offer, request and uptake in high risk patients during the 1991-92 season. Epidemiol Infect 1993; 111: 347-355.

169. Duclos P, Hatcher J. Epidemiology of influenza vaccination in Canada. Can J Public Health 1993; 84: 311-315.

170. Pérez-Tirse J, Gross PA. Review of cost-benefit analyses of influenza vaccine. Pharmaco Economis 1992; 2: 198-206.

171. Ballada D, Biasio LR, Cascio G et al. Attitudes and behavior of health care personnel regarding influenza vaccination. Eur J Epidemiol 1994; 10: 63-68.

172. Serwint J. Pediatrician-dependent barriers in influenza vaccine administration. Pediatr Infect Dis J 1993; 12: 956-958.

173. Fedson DS, Hannoun C, Leese J et al. Influenza vaccination in 18 developed countries, 1982-1992. Vaccine 1995; 13: 623-627.

174. Webster RG. While awaiting the next pandemic of influenza A. Br Med J 1994; 309: 1179- 1180.

175. Shortridge KF. The next pandemic influenza virus? Lancet 1995; 346: 1210-1212.

176. World Health Organization. Press release WHO/60. 21 August, 1997.

177. Chalumeau HP. Vaccine manufacture at the time of a pandemic influenza. Eur J Epidemiol 1994; 10: 487490.

178. Gross PA. Preparing for the next innuenza pandemic. A reemerging infection. Am Intern Med 1996; 124: 682-685.

179. Aymard M, Cox NJ, Dubois G et al. Recomendations of the 7th European Meeting of Influenza and its Prevention (Berlin, September 1993). Eur J Epidemiol 1994; 10: 525-526.

180. Jack DB. Getting ready for the next influenza pandemic. Lancet 1996; 347: 1252.

181. Murphy BR. Use of live attenuated cold-adapted influenza A reassortant virus vaccines in infants, children, young adults and elderly adults. Infect Dis Clin Pract 1993; 2: 174-181.

182. Edwards KM, Dupont WD, Westrich MK, Plumer WDJr, Palmer PS, Wright PF. A randomized controlled trial of coldadapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994; 169: 68-76.

183. Horwitz RJ, Arnon R. Influenza. En: Nicholson BH, ed. Synthetic vaccines. London: Blackwell, 1994; 471493.

184. Robinson HL, Hunt LA, Webster RG. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 1993; 11: 957960.

185. Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745-1749.